Hyperlipidaemia and cardiovascular disease

Nicholls, 2012, Is niacin ineffective Or did AIM-HIGH miss its target Cleve Clin J M, ed, 79, 38

Otvos, 2011, The surprising AIM-HIGH results are not surprising when viewed through a particle lens., J Clin Lipidol, 5, 368, 10.1016/j.jacl.2011.06.012

Lyngdoh, 2011, Association of statins with inflammatory cytokines: a population-based Colaus study., Atherosclerosis, 219, 253, 10.1016/j.atherosclerosis.2011.07.117

DeFilippis, 2011, The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in Multi-Ethnic Study of Atherosclerosis (MESA)., J Am Coll Cardiol, 58, 2076, 10.1016/j.jacc.2011.08.022

Fayad, 2011, dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial., Lancet, 378, 1547, 10.1016/S0140-6736(11)61383-4

Barter, 2007, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events., N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628

Ridker, 2008, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein., N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646

Ridker, 2009, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial., Lancet, 373, 1175, 10.1016/S0140-6736(09)60447-5

Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins., Circulation, 110, 3512, 10.1161/01.CIR.0000148955.19792.8D

Airan-Javia, 2009, Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy., Am Heart J, 157, 687e1, 10.1016/j.ahj.2009.01.001

Guyton, 2008, Lipid-altering efficacy and safety of ezetimibesimvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia., J Am Coll Cardiol, 51, 1564, 10.1016/j.jacc.2008.03.003

Wi, 2010, Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160mg and niacin 1500mg., Atherosclerosis, 213, 235, 10.1016/j.atherosclerosis.2010.08.068

Thoenes, 2007, The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome., Int J Clin Pract, 61, 1942, 10.1111/j.1742-1241.2007.01597.x